盐酸缬更昔洛韦片的注意事项

Recently, a patient asked: Is there anything I need to pay attention to when taking it? Let's take a look.

Acute Renal Failure: Acute renal failure may occur, ensure adequate hydration and use with caution in patients receiving concomitant nephrotoxic drugs.

Hematological disorders: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow failure, including aplastic anemia. May occur at any time during treatment and worsen with continued use; cell counts usually begin to recover within 3-7 days of stopping treatment. Do not use if the absolute neutrophil count is <500 cells/MM3, platelet count <25,000/m3, or hemoglobin <8 g/dl; use with caution in patients with myelosuppression, cytopenia, or patients receiving myelosuppressive drugs/radiation. Monitor CBC and platelet counts at baseline and frequently during treatment, especially in infants and patients with renal impairment, patients with prior drug-induced leukopenia, and patients with neutrophil counts <1000 cells/mm3 at the start of treatment. 

Carcinogenicity/Teratogenicity: May temporarily or permanently inhibit sperm production and suppress fertility; may cause birth defects and cancer in humans. Due to its teratogenicity, women should take a pregnancy test before initiating pregnancy and use effective contraception during treatment and for 30 days after treatment; men should use barrier contraception during treatment and for 90 days after treatment. 

Renal Impairment: Use with caution in patients with impaired renal function; dose adjustment required.

Elderly: Acute renal failure may occur in elderly patients with or without renal impairment, use with caution and adjust dosage based on renal function.

Liver Transplant Recipients: Not suitable for use in liver transplant patients (a higher incidence of tissue-infiltrating cytomegalovirus (CMV) was observed in the trial compared with oral ganciclovir). 

Pediatrics: The preferred dosage form for pediatric patients is the oral solution; however, valganciclovir hydrochloride tablets may be used as long as the calculated dose is within 10% of the available tablet strength (450 mg). The use of valganciclovir hydrochloride tablets in the treatment of congenital cytomegalovirus disease has not been evaluated. 

The above are the precautions provided by our Medical Companion Travel Overseas Medical Consulting Service Company for you. Patients must strictly follow the doctor's instructions to take it.